RATIONALE: Gathering information about patients with myelodysplastic syndrome or acute myeloid leukemia who are discharged after finishing chemotherapy, or who stay in the hospital until blood counts return to normal, may help doctors learn more about the safety of allowing patients to leave the hospital early, the patient's quality of life, use of medical services, and the cost of these services associated with such a policy.
PURPOSE: This clinical trial is studying early discharge and outpatient care in patients who have undergone chemotherapy for myelodysplastic syndrome or acute myeloid leukemia.
- Age 18-75 years.
- Diagnosis of MDS or AML other than APL with t(15;17)(q22;q12), (PML/RAR), or variants according to the 2008 WHO classification.
- Will undergo AML-like intensive induction, re-induction, or consolidation chemotherapy within 1 week, or have started therapy within last 72 hours.
- Drug hypersensitivities or allergies disabling use of prophylactic antimicrobials.
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.